Showing results (151-160 of 223) with videos related to

Sort By:
Pageof 23
Cancers|September 23, 2022
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA StudyDiane Evrard, Clément Dumont, Michel Gatineau, et al.
Journal for Immunotherapy of Cancer|August 16, 2023
PPARγ activation modulates the balance of peritoneal macrophage populations to suppress ovarian tumor growth and tumor-induced immunosuppressionMélissa Prat, Kimberley Coulson, Clément Blot, et al.
Journal of Neuro-Oncology|August 10, 2016
Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?Jonathan Khalifa, Fatima Tensaouti, Jean-Albert Lotterie, et al.
Targeted Oncology|November 20, 2012
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trialChristophe Le Tourneau, Maud Kamal, Olivier Trédan, et al.
Clinical Colorectal Cancer|February 28, 2026
Lenvatinib Plus Pembrolizumab for Patients With Previously Treated Advanced Colorectal Cancer: Results From the Phase II LEAP-005 StudyIván Victoria Ruiz, Nataliya V Uboha, Rahima Jamal, et al.
Oncoimmunology|November 1, 2021
Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancersJuan-Pablo Cerapio, Marion Perrier, Camille-Charlotte Balança, et al.
European Journal of Cancer (Oxford, England : 1990)|January 8, 2022
Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trialSophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I StudyDaniel P Petrylak, Yohann Loriot, David R Shaffer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerHope S Rugo, Jean-Pierre Delord, Seock-Ah Im, et al.
Lung Cancer (Amsterdam, Netherlands)|May 5, 2023
Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket studyMatthew G Krebs, Jean-Pierre Delord, Thomas R Jeffry Evans, et al.
Pageof 23